927P Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Hoffman-Censits J, Rosenberg J, van Der Heijden M, Dreicer R, Gracia J, Petrylak D, Retz M, Sabbatini R, Naglieri E, Caserta C, Maruzzo M, Iacovelli R, Galli L, McDermott R, Barrera R, Bonfill T, De Ducla S, Ding B, Linsenmeier J, Sternberg C. 927P Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC). Annals Of Oncology 2019, 30: v372-v373. DOI: 10.1093/annonc/mdz249.026.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaBody mass indexF. Hoffmann-La RochePersonal feesBristol-Myers SquibbHoffmann-La RocheCohort 1Roche/GenentechMedian body mass indexSeattle GeneticsMedian treatment durationObjective response rateSignificant OS differenceOverall survival outcomesDifferent treatment settingsSignificant differencesBristol-Meyers SquibbAtezolizumab monotherapyECOG PSFortress BiotechMale ptsMedian OSOS benefitWeill Cornell MedicineTreatment discontinuation901O EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
Hoimes C, Rosenberg J, Srinivas S, Petrylak D, Milowsky M, Merchan J, Bilen M, Gupta S, Carret A, Yuan N, Melhem-Bertrandt A, Flaig T. 901O EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Annals Of Oncology 2019, 30: v356. DOI: 10.1093/annonc/mdz249.Peer-Reviewed Original ResearchBristol-Myers SquibbMetastatic urothelial carcinomaAdverse eventsSeattle GeneticsUrothelial carcinomaDay 1Common treatment-emergent adverse eventsEli LillyTreatment-emergent adverse eventsDose-escalation cohortsGenentech/RocheImmune-mediated eventsPhase 1b studyPost-baseline scanSafety/tolerabilityManageable safety profileSystemic steroid treatmentKey secondary objectiveStandard of careBavarian NordicFortress BiotechMonotherapy dataRECIST 1.1Encouraging efficacyPrimary endpoint